港股异动 | 圣诺医药-B(02257)午后涨近17% 获纳入恒生指数系列成份股及富时罗素亚太区域指数

智通财经2022-08-22

智通财经APP获悉，圣诺医药-B(02257)午后涨近17%，截至发稿，涨13.14%，报68港元，成交额1362.34万港元。消息面上，圣诺医药公布，已获恒生指数有限公司纳入恒生指数系列成份股，相关变动将于2022年9月5日起生效。此外，富时罗素公布了富时全球股票指数系列亚太区域指数半年一次的审查结果，其中，圣诺医药-B获纳入小盘指数。值得注意的是，圣诺医药此前公布，公司核心产品小干扰核酸(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2261878519?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-08-22 14:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2261878519","market":"sh","top_or_hot":-1,"title":"港股异动 | 圣诺医药-B(02257)午后涨近17% 获纳入恒生指数系列成份股及富时罗素亚太区域指数","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，圣诺医药-B(02257)午后涨近17%，截至发稿，涨13.14%，报68港元，成交额1362.34万港元。消息面上，圣诺医药公布，已获恒生指数有限公司纳入恒生指数系列成份股，相关变动将于2022年9月5日起生效。此外，富时罗素公布了富时全球股票指数系列亚太区域指数半年一次的审查结果，其中，圣诺医药-B获纳入小盘指数。值得注意的是，圣诺医药此前公布，公司核心产品小干扰核酸(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/775429.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 圣诺医药-B(02257)午后涨近17% 获纳入恒生指数系列成份股及富时罗素亚太区域指数</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 圣诺医药-B(02257)午后涨近17% 获纳入恒生指数系列成份股及富时罗素亚太区域指数\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-22 14:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/775429.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，圣诺医药-B(02257)午后涨近17%，截至发稿，涨13.14%，报68港元，成交额1362.34万港元。消息面上，圣诺医药公布，已获恒生指数有限公司纳入恒生指数系列成份股，相关变动将于2022年9月5日起生效。此外，富时罗素公布了富时全球股票指数系列亚太区域指数半年一次的审查结果，其中，圣诺医药-B获纳入小盘指数。值得注意的是，圣诺医药此前公布，公司核心产品小干扰核酸(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/775429.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSI","symbol_name":"恒生指数","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/775429.html","article_id":"2261878519","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2261878519","pubTimestamp":1661151542,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，圣诺医药-B(02257)午后涨近17%，截至发稿，涨13.14%，报68港元，成交额1362.34万港元。消息面上，圣诺医药公布，已获恒生指数有限公司纳入恒生指数系列成份股，相关变动将于2022年9月5日起生效。此外，富时罗素公布了富时全球股票指数系列亚太区域指数半年一次的审查结果，其中，圣诺医药-B获纳入小盘指数。值得注意的是，圣诺医药此前公布，公司核心产品小干扰核酸(siRNA)候选药物STP705用于治疗面部原位鳞状细胞皮肤癌(isSCC)的I/II期临床试验已完成首例受试者系统给药。本试验于2022年8月在美国启动，预计将于2023年第一季度完成。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"513600":"恒生指数ETF","HSI":"恒生指数","SRTY":"罗素2000指数三倍做空ETF-ProShares","TNA":"罗素2000指数三倍做多ETF-Direxion","TWM":"罗素2000指数两倍做空ETF","BK4534":"瑞士信贷持仓","02833":"恒指ETF","BK4535":"淡马锡持仓","UWM":"罗素2000指数ETF两倍做多","IWM":"罗素2000指数ETF","BK4550":"红杉资本持仓","RWM":"罗素2000指数反向ETF","TZA":"罗素2000指数三倍做空ETF","IWN":"罗素2000价值股指数ETF-iShares","BK1161":"生物科技","BK4581":"高盛持仓","IWO":"罗素2000成长股指数ETF","02257":"圣诺医药-B"},"translate_title":"Hong Kong stocks changed Shengnuo Medicine-B (02257) rose nearly 17% in the afternoon and was included in the Hang Seng Index Series and FTSE Russell Asia Pacific Regional Index","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"513600":0.6,"IWM":1,"HSI":1,"02257":1,"MRTYmain":0.6,"UWM":0.6,"TZA":0.6,"TWM":0.6,"TNA":0.6,"SRTY":0.6,"RWM":0.6,"IWO":0.6,"IWN":0.6,"MNQmain":0.6,"MCHmain":0.6,"HHImain":0.6,"02833":0.6},"content_text":"智通财经APP获悉，圣诺医药-B(02257)午后涨近17%，截至发稿，涨13.14%，报68港元，成交额1362.34万港元。消息面上，圣诺医药公布，已获恒生指数有限公司纳入恒生指数系列成份股，相关变动将于2022年9月5日起生效。此外，富时罗素公布了富时全球股票指数系列亚太区域指数半年一次的审查结果，其中，圣诺医药-B获纳入小盘指数。值得注意的是，圣诺医药此前公布，公司核心产品小干扰核酸(siRNA)候选药物STP705用于治疗面部原位鳞状细胞皮肤癌(isSCC)的I/II期临床试验已完成首例受试者系统给药。本试验于2022年8月在美国启动，预计将于2023年第一季度完成。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2261878519"}